Utrecht, The Netherlands
NTrans Technologies BV was founded in 2015 based on a proprietary platform technology for the intracellular delivery of bioactive molecules developed at the Hubrecht Institute of the Royal Netherlands Academy of Sciences.
We are further developing this technology for both research and clinical purposes as a method for the delivery of biologicals that is safe, non-toxic, highly efficient, and easy to use.
Our goal is to be a leader in technologies for the transduction of proteins and other bioactive molecules into primary cells.
We offer licensing of the unique transduction platform with thorough technical support to optimize your transduction.
NTrans has successfully completed the H2020-ENTRANCE project. The results of the project have been publised on the CORDIS website in six languages at: https://cordis.europa.eu/article/id/415539-itop-technology-for-protein-delivery-into-cells?WT.mc_id=exp NTrans researchers have optimised the composition of iTOP and developed protocols for the most effective transfection of various cell types including cell lines, stem cells and
Last May at the BCF Career Event NTrans Technologies has been awarded the BCF Scale-up Award. What is the story behind this upcoming life science business? https://www.bcfcareer.nl/bcf-scale-up-award-winner-2019/ The story of NTrans Technologies starts in 2015 in the laboratories of the Hubrecht Institute of the Royal Netherlands Academy of Sciences (NWO).